Pharmaceutical sponsor
Shandong Suncadia Medicine Co., Ltd. Clinical Trials
Studies where Shandong Suncadia Medicine Co., Ltd. is the lead sponsor: its pipeline by phase, what is enrolling now and where. Studies it supports as a collaborator are in the search.
In numbers
Open to volunteers: recruiting, not yet recruiting or enrolling by invitation. Active adds studies under way that have stopped recruiting.
Open to volunteers
All 33Uncontrolled or Resistant Hypertension
A Trial of HRS-1780 in Participants With Uncontrolled Hypertension or Resistant Hypertension.
The study is being conducted to evaluate the efficacy and safety of HRS-1780 in participants with uncontrolled hypertension or resistant hypertension.
- Trial name
- NCT07708441
- Testing
- HRS-1780 tablet
- Where
- 2 sites in China
- Volunteers
- 914 people
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.
Breast Cancer
A Drug-Drug Interaction Study of Rifampicin and Oral HRS-8080
A single-center, single-arm, open-label, fixed-sequence study is planned to enroll 18 healthy participants (6-9 females). The study consists of a screening period, an observation period, and a safety follow-up period.
- Trial name
- NCT07876596
- Testing
- HRS-8080, Rifampicin
- Where
- China
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.
Locally Advanced Breast Cancer, Metastatic Breast Cancer
A Phase 3 Study of HRS-8080 Versus Treatment Chosen by Physicians in Locally Advanced and Metastatic Breast Cancer
This study is a multicenter, open-label, randomized controlled Phase 3 clinical trial. It is planned to enroll 240 female patients with locally advanced or metastatic breast cancer followed by disease progression after previous…
- Trial name
- NCT07024173
- Testing
- HRS-8080 Tablet, Fulvestrant injection, Exemestane tablets
- Where
- 2 sites in China
- Volunteers
- 240 people
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.
Hypertension With Overweight or Obesity
Phase III Study of HRS-7535 for Hypertension With Overweight or Obesity
The main objective of this study is to demonstrate the superior efficacy of HRS-7535 in controlling blood pressure compared to placebo in subjects with hypertension and overweight or obesity;
- Trial name
- NCT07528027
- Testing
- HRS-7535
- Where
- 2 sites in China
- Volunteers
- 648 people
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.
Obese and Metabolic Disorders
Safety and Pharmacokinetics of HRS-1597 Tablets in Healthy and Obese Participants: A Phase 1 Study
This is a Phase 1, single-center, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and pharmacokinetics of HRS-1597 tablets following single-dose administration in healthy participants and…
- Trial name
- NCT07808918
- Testing
- HRS-1597
- Where
- China
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.
Acute Gouty Arthritis
Clinical Study of HRS-2129 for Acute Gouty Arthritis
The study is being conducted to evaluate the safety, and efficacy of HRS-2129 for acute gouty arthritis. To explore the reasonable dosage of HRS-2129 for acute gouty arthritis.
- Trial name
- NCT07706777
- Testing
- HRS-2129 Tablet
- Where
- 2 sites in China
- Volunteers
- 90 people
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.
Heart Failure
A Clinical Study of HRS-7156 in Healthy Participants
The purpose of this Phase I study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of HRS-7156 in healthy participants.
- Trial name
- NCT07601087
- Testing
- HRS-7156
- Where
- China
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.
Lipoprotein Disorder
Study of Oral HRS-5346 in Adult Patients With Elevated Lipoprotein(a) and High Risk of Cardiovascular Events
This study is designed to evaluate the efficacy and safety of HRS-5346 Tablets in participants with high cardiovascular event risk and elevated Lp(a), and to investigate the appropriate dosage of HRS-5346 Tablets
- Trial name
- NCT07767513
- Testing
- HRS-5346
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.
Lipoprotein Disorder
Phase I Clinical Study Evaluating the Relative Bioavailability of Different Formulations of HRS-5346 in Healthy Participants
This study is a single center, randomized, open label crossover trial planned to include 50 healthy participants to evaluate the relative bioavailability of HRS-5346 new and old formulations in healthy participants.
- Trial name
- NCT07752069
- Testing
- HRS-5346
- Where
- China
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.
Chronic Kidney Disease
A Phase III Clinical Study on the Efficacy and Safety of HRS-1780 in the Treatment of Patients With Chronic Kidney Disease
The study is a Phase III clinical trial to evaluate the superiority of HRS-1780 tablets compared with placebo in delaying renal function decline in participants with chronic kidney disease (CKD) on the basis of standard treatment.
- Trial name
- NCT07419828
- Testing
- HRS-1780 tablets
- Where
- China
- Volunteers
- 5,386 people
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.